Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
Year: 2022
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2 Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022. VE difference (VED) estimates were assessed using random-effects and meta-regression analyses were performed for evaluating VE over time. Compared to full dose, booster dose of overall vaccines provided better protection against any and severe Omicron infections within 3 months (p < 0.001), and within 3 months or more in any, severe, and symptomatic infections (p < 0.001). From meta-regression analysis of overall vaccines, the full-dose VE against any and symptomatic Omicron infections reduced per month by 2.45% and 5.5%, respectively; whereas booster dose effectiveness against any and symptomatic Omicron infections reduced per month by 1.79% and 1.14%, respectively. The VE estimates of booster dose provide excellent protection against symptomatic infection compared to full dose. The VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 against Omicron infection are generally moderate, despite the VE estimates declining over time.
Source: Vaccines
Authors: Nando Reza Pratama(Conceptualization, Data curation, Formal analysis, Methodology, Software, Supervision, Writing – original draft), Ifan Ali Wafa(Conceptualization, Investigation, Methodology, Resources, Supervision, Validation, Writing – original draft), David Setyo Budi(Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing – original draft), Henry Sutanto(Supervision, Visualization, Writing – review & editing), Tri Pudy Asmarawati(Supervision, Visualization, Writing – review & editing), Gema Barlian Effendi(Visualization, Writing – review & editing), Citrawati Dyah Kencono Wungu(Supervision, Visualization, Writing – review & editing)
Institutions: Universitas Airlangga, Maastricht University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,303
OpenAlex ID: W4311884377
